irradiated 4T1.2 whole tumor cell vaccine

Irradiated 4T1.2 whole tumor cell vaccine is an experimental, preclinical cancer vaccine consisting of lethally irradiated 4T1.2 mouse mammary tumor cells. The 4T1.2 cell line is a highly metastatic, poorly immunogenic subclone of the 4T1 murine breast cancer model, which closely mimics human stage IV triple-negative breast cancer. By irradiating the cells, their proliferative capacity is destroyed while preserving their cell-surface tumor-associated antigens. When administered as a vaccine, it is designed to stimulate the host immune system, promoting tumor-specific interferon-gamma (IFN-γ) production, enhancing CD4+ and CD8+ T-cell responses, and reducing the accumulation of immunosuppressive splenic myeloid-derived suppressor cells (MDSCs). It has been studied preclinically, often in combination with lifestyle interventions (such as diet and exercise-induced weight maintenance) or immune checkpoint inhibitors (like anti-PD-1 antibodies), to delay primary mammary tumor growth and reduce metastatic burden.

Other names

4T1.2 whole tumor cell vaccineirradiated 4T1.2 cellsirradiated4T1.2 cellsirradiated-4T1.2 cellsirradiated 4T1.2 vaccineirradiated4T1.2 vaccineirradiated-4T1.2 vaccine